The Goldman Sachs Group Reiterates “GBX 6,950” Price Target for AstraZeneca (LON:AZN)

The Goldman Sachs Group set a GBX 6,950 ($88.58) price target on AstraZeneca (LON:AZN – Get Rating) in a research note published on Friday morning, Borsen Zeitung reports.

AZN has been the subject of a number of other reports. Barclays reissued an overweight rating and set a £115 ($146.57) price objective on shares of AstraZeneca in a report on Wednesday, April 13th. UBS Group set a £105 ($133.83) price objective on AstraZeneca in a report on Monday, March 7th. Credit Suisse Group set a £110 ($140.20) price target on AstraZeneca in a report on Friday, April 8th. JPMorgan Chase & Co. set a £120 ($152.94) price target on AstraZeneca in a report on Wednesday. Finally, Deutsche Bank Rese… set a £115 ($146.57) price target on AstraZeneca in a report on Wednesday, April 6th. Two research analysts have rated the stock with a sell rating and twelve have given a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of Buy and a consensus target price of £104.36 ($133.01).

Shares of LON AZN opened at £106.88 ($136.22) on Friday. The stock has a market cap of £165.61 billion and a PE ratio of 1,696.51. The business has a fifty day moving average of GBX 9,833.12 and a two-hundred day moving average of GBX 9,063.05. AstraZeneca has a 52-week low of GBX 7,502 ($95.62) and a 52-week high of £110 ($140.20). The company has a debt-to-equity ratio of 82.58, a quick ratio of 0.67 and a current ratio of 1.16.

The company also recently disclosed a dividend, which was paid on Monday, March 28th. Investors of record on Thursday, February 24th were given a GBX 145.30 ($1.85) dividend. This represents a yield of 1.74%. This is a positive change from AstraZeneca’s previous dividend of $64.80. The ex-dividend date was Thursday, February 24th. AstraZeneca’s dividend payout ratio (DPR) is presently 44.51%.

About AstraZeneca (Get Rating)

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases.

Further Reading